Member Info for daveycaferacer

it does also prompt the question why an anti Vaxxer would invest in a Biotech Company!!

Levs, it's not just about you though is it...... everyone has at least some level of responsibility towards others. Most sensible people realise that vaccines protect others as well as the individual. If you only care about yourself and no one else, including family members, I suggest you stick with your strategy and don't get vaccinated.

bmo3, will let you know what happens and if i have any side effects

it's all about risk, whether you'd take what is probably an extremely small risk with the vaccine or what is almost certainly a much higher risk of getting and potentially dying from Covid-19. The trials were accelerated yes, but all the usual protocols and standards were adhered to and it should be remembered that is is not an entirely new vaccine, it is a modified version of a SARS vaccine that has been proven to be entirely safe. I have lymphoma so I'll happily take it as soon as it's offered to me.

" it should be the MP's they should lead the nation as they feel the vaccine for the public."

The problem is, if they do that they will get a barrage of criticism for trying to protect themselves first, before others. They are on a hiding to nothing.......

I was joking letsbecool but we all have a moral responsibility to take the vaccine, to protect others, if not ourselves

".he cabinet ministers should be filmed in front of the media taking the vaccine first "

I disagree letsbecool, I think you should take it first

fullfathom, currentluy it would be through Tiziana. Currently the only thing that has occurred is a capital reduction. However, there is nothing to stop Accustem issuing a Press Release however, as they are a Company in their own right already.

"On a separate note, anyone know if Accustem can issue their own RNSs ? Or would it still be Tiziana ?"

Only Companies listed on the London Stock Exchange can issues RNS's and they are not currently listed on the London Stock Exchange.

It's interesting to note jatw we are also recruiting a Head of Market Access to cover access to Medicare and Medicaid access programs. To your point about the mixed approach, that may be the case. For now building a U.S Sales Team and retaining 100% of the commercial benefits of Surufatinib and Fruquintinib should provide material uplifts in valuation over the next 5 years. We may well get confirmation of Surufatinib NDA submission to the FDA within the next few weeks.

It is interesting to peruse the Company's Careers website. Of particular note are a number of Sales related roles including a Head of Sales/Sales Training, a clear demonstration of the strategy to build a local specialist Oncology sales/detailing Team rather than partner. I think this is a great strategy allowing to Company to retain all the financial benefits of wholly owned assets.

https://www.chi-med.com/career-opportunities/

NASDAQ opens again tomorrow at 09:30 and closes at 13:00, back to normal hours on Monday

A great list jatw, nice summary and I'd be happy to have just one of those......

Yes, most Brokers have said they will not credit accounts until they receive the shares and the shares are trade-able, so I think you will find most people are still waiting. Hopefully the listing will occur before the end of the year as the Company has suggested.

"What on Earth has happened to this company last few months ???? My investment is looking grim within the sp at present but the amount of Trials etc within the background why are they always so bloody slow to release anything ??"

Welcome to the world of Biopharma investing

I have no issues with the pipeline, the science or the overall progress of the Company - it is the Corporate strategy and associated actions that have been handled very poorly.

I would also recommend they avoid platforms like Redchip which target the Robinhood flip-flop day-traders in the U.SD. and instead focus on the professional U.S. based Biopharma Investment Community.

Unfortunately the Board / Management Team have lost investor trust with their finger in the air timescales. They need better Advisors, or they need ti listen properly to the ones they have. Kunwar is a scientist and is probably not best suited to managing the timing of corporate actions. I am not sure what Gabriele does on a day to day basis, it almost seems as if it is a personal lifestyle business for him. Ultimately they seem to over-promise and under-deliver to the market, which is why the market is behaving as it does. A few months ago they sent out an RNS saying they were de-listing in London altogether, followed a few months later by a main market listing.

These mixed messages, pullbacks, reversals and over-egging the pudding must surely be unnerving to institutional Investors.

actually scrub Savo, that will be down to AZ and probably not near approval until H1, 21

or even Savo of course!